Effect of fosfomycin-induced hypernatremia on patients' hospital stay length and survival.
Fosfomycin
Hospital stay length
Hypernatremia
Survival
Journal
Irish journal of medical science
ISSN: 1863-4362
Titre abrégé: Ir J Med Sci
Pays: Ireland
ID NLM: 7806864
Informations de publication
Date de publication:
20 May 2024
20 May 2024
Historique:
received:
24
04
2024
accepted:
15
05
2024
medline:
20
5
2024
pubmed:
20
5
2024
entrez:
20
5
2024
Statut:
aheadofprint
Résumé
Hypernatremia is a possible side effect of intravenous fosfomycin. The aim of this study was to investigate the effects of changes in sodium (Na) levels on hospital stay and survival in patients hospitalized in the intensive care unit receiving fosfomycin. This study was conducted retrospectively on the files of patients over the age of 60, who were admitted to the Internal Medicine Intensive Care Unit. Plasma sodium levels were observed and documented over a period of 14 days. The patients were divided into two groups (Hypernatremia group Na > 145 mEq/L vs normonatremia group 135-145 mEq/L). In addition, daily sodium changes were noted for 14 days in patients. The mean age of the patients was 75 years. Hospitalization days were longer for hypernatremia patients (31.5 days vs 41 days, p = 0.003). Patients with hypernatremia had an extended duration of stay in the intensive care unit. (21 days vs 31 days p = 0.002). The 1-month survival rate was 61.4% in patients with hypernatremia and 24.9% in patients without hypernatremia (p = 0.004). The absence of hypernatremia increases mortality by 2.09 times (95% CI 1.35-3.23). When discharge and mortality rates were analyzed according to sodium fluctuation, discharged patients exhibited a lower sodium fluctuation (4 min/max (-10/19) vs 6 min/max (-16/32) p < 0.001). In conclusion, the strength of our study is that it specifically focuses on the consequences of the sodium fluctuation on patient management and provides results.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Hypernatremia is a possible side effect of intravenous fosfomycin. The aim of this study was to investigate the effects of changes in sodium (Na) levels on hospital stay and survival in patients hospitalized in the intensive care unit receiving fosfomycin.
SUBJECTS AND METHODS
METHODS
This study was conducted retrospectively on the files of patients over the age of 60, who were admitted to the Internal Medicine Intensive Care Unit. Plasma sodium levels were observed and documented over a period of 14 days. The patients were divided into two groups (Hypernatremia group Na > 145 mEq/L vs normonatremia group 135-145 mEq/L). In addition, daily sodium changes were noted for 14 days in patients.
RESULTS
RESULTS
The mean age of the patients was 75 years. Hospitalization days were longer for hypernatremia patients (31.5 days vs 41 days, p = 0.003). Patients with hypernatremia had an extended duration of stay in the intensive care unit. (21 days vs 31 days p = 0.002). The 1-month survival rate was 61.4% in patients with hypernatremia and 24.9% in patients without hypernatremia (p = 0.004). The absence of hypernatremia increases mortality by 2.09 times (95% CI 1.35-3.23). When discharge and mortality rates were analyzed according to sodium fluctuation, discharged patients exhibited a lower sodium fluctuation (4 min/max (-10/19) vs 6 min/max (-16/32) p < 0.001).
CONCLUSION
CONCLUSIONS
In conclusion, the strength of our study is that it specifically focuses on the consequences of the sodium fluctuation on patient management and provides results.
Identifiants
pubmed: 38767810
doi: 10.1007/s11845-024-03718-1
pii: 10.1007/s11845-024-03718-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.
Références
Matthews PC, Barrett LK, Warren S et al (2016) Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. BMC Infect Dis 16(1):556
doi: 10.1186/s12879-016-1888-1
pubmed: 27729016
pmcid: 5057270
Hashemian SMR, Farhadi Z, Farhadi T (2019) Fosfomycin: the characteristics, activity, and use in critical care. Ther Clin Risk Manag 27(15):525–530
doi: 10.2147/TCRM.S199119
Cao Y, Peng Q, Li S et al (2019) The intriguing biology and chemistry of fosfomycin: the only marketed phosphonate antibiotic. RSC Adv 9(72):42204–42218
doi: 10.1039/C9RA08299A
pubmed: 35548698
pmcid: 9088020
Anastasia A, Bonura S, Rubino R et al (2023) The use of intravenous fosfomycin in clinical practice: a 5-year retrospective study in a tertiary hospital in Italy. Antibiotics (Basel) 12(6):971
doi: 10.3390/antibiotics12060971
pubmed: 37370290
Ruiz Ramos J, Salavert Lletí M (2019) Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens. Rev Esp Quimioter 32(Suppl 1):45–54
pubmed: 31131592
pmcid: 6555168
Sastry S, Doi Y (2016) Fosfomycin: resurgence of an old companion. J Infect Chemother 22(5):273–80
doi: 10.1016/j.jiac.2016.01.010
pubmed: 26923259
pmcid: 4833629
Iarikov D, Wassel R, Farley J, Nambiar S (2015) Adverse events associated with fosfomycin use: review of the literature and analyses of the FDA adverse event reporting system database. Infect Dis Ther 4(4):433–458
doi: 10.1007/s40121-015-0092-8
pubmed: 26437630
pmcid: 4675770
Scavone C, Mascolo A, Bernardi FF et al (2022) Hypernatremia during intravenous treatment with fosfomycin: a retrospective medical record review study and an analysis of spontaneous reports in the eudravigilance database. Front Pharmacol 29(13):844122
doi: 10.3389/fphar.2022.844122
Giske CG, Turnidge J, Cantón R, Kahlmeter G (2022) EUCAST Steering Committee. Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). J Clin Microbiol 60(3):e0027621
doi: 10.1128/jcm.00276-21
pubmed: 34346716
Tauseef A, Zafar M, Syed E et al (2021) Prognostic importance of deranged sodium level in critically ill patients: a systemic literature to review. J Family Med Prim Care 10(7):2477–2481
doi: 10.4103/jfmpc.jfmpc_2291_20
pubmed: 34568122
pmcid: 8415657
Polderman KH, Schreuder WO, Strack van Schijndel RJ, Thijs LG (1999) Hypernatremia in the intensive care unit: an indicator of quality of care? Crit Care Med 27(6):1105–1108
doi: 10.1097/00003246-199906000-00029
pubmed: 10397213
Olsen MH, Møller M, Romano S et al (2020) Association between ICU-acquired hypernatremia and in-hospital mortality: data from the medical information mart for intensive care III and the electronic ICU collaborative research database. Crit Care Explor 2(12):e0304
doi: 10.1097/CCE.0000000000000304
pubmed: 33354677
pmcid: 7746205
Yun G, Baek SH, Kim S (2023) Evaluation and management of hypernatremia in adults: clinical perspectives. Korean J Intern Med 38(3):290–302
doi: 10.3904/kjim.2022.346
pubmed: 36578134
Tsegka KG, Voulgaris GL, Kyriakidou M et al (2022) Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review. Expert Rev Anti Infect Ther 20(1):33–43
doi: 10.1080/14787210.2021.1932463
pubmed: 34030567
Chen T-T, Chang Y-F, Wu Y-C (2023) Clinical use of intravenous fosfomycin in critical care patients in Taiwan. Pathogens 12(6):841
doi: 10.3390/pathogens12060841
pubmed: 37375531
pmcid: 10301606
Putensen C, Ellger B, Sakka SG et al (2019) Current clinical use of intravenous fosfomycin in ICU patients in two European countries. Infection 47(5):827–836
doi: 10.1007/s15010-019-01323-4
pubmed: 31190298
Grabein B, Graninger W, Rodríguez Baño J, Dinh A, Liesenfeld DB (2017) Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect 23:363–372
doi: 10.1016/j.cmi.2016.12.005
pubmed: 27956267
Pontikis K, Karaiskos I, Bastani S et al (2014) Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing gram-negative bacteria. Int J Antimicrob Agents 43:52–59
doi: 10.1016/j.ijantimicag.2013.09.010
pubmed: 24183799
Lombardi G, Ferraro PM, Calvaruso, and others (2019) Sodium fluctuations and mortality in a general hospitalized population. Kidney Blood Press Res 44(4):604–614
doi: 10.1159/000500916
pubmed: 31330509
Grim CC, Termorshuizen F, Bosman RJ and others (2021) Association between an increase in serum sodium and in-hospital mortality in critically ill patients. Crit Care Med 49(12):2070–2079
doi: 10.1097/CCM.0000000000005173
pubmed: 34166287
pmcid: 8594512
Ng ACC, Chow V, Yong ASC and others (2013) Fluctuation of serum sodium and its impact on short and long-term mortality following acute pulmonary embolism. PLoS ONE 8(4):e61966
doi: 10.1371/journal.pone.0061966
pubmed: 23620796
pmcid: 3631139
Eagles ME, Tso MK, Macdonald RL (2018) Significance of fluctuations in serum sodium levels following aneurysmal subarachnoid hemorrhage: an exploratory analysis. J Neurosurg 131(2):420–425
doi: 10.3171/2018.3.JNS173068
pubmed: 30117765
Marshall DC, Salciccioli JD, Goodson RJ and others (2017) The association between sodium fluctuations and mortality in surgical patients requiring intensive care. J Crit Care 40:63–68
doi: 10.1016/j.jcrc.2017.02.012
pubmed: 28347943
pmcid: 5679219